JP2025513502A - 液体組成物 - Google Patents
液体組成物 Download PDFInfo
- Publication number
- JP2025513502A JP2025513502A JP2024562212A JP2024562212A JP2025513502A JP 2025513502 A JP2025513502 A JP 2025513502A JP 2024562212 A JP2024562212 A JP 2024562212A JP 2024562212 A JP2024562212 A JP 2024562212A JP 2025513502 A JP2025513502 A JP 2025513502A
- Authority
- JP
- Japan
- Prior art keywords
- aqueous composition
- pharma
- acceptable salt
- rilpivirine
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333556P | 2022-04-22 | 2022-04-22 | |
| US63/333,556 | 2022-04-22 | ||
| EP22173922 | 2022-05-17 | ||
| EP22173922.0 | 2022-05-17 | ||
| PCT/EP2023/060689 WO2023203258A1 (en) | 2022-04-22 | 2023-04-24 | Liquid compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513502A true JP2025513502A (ja) | 2025-04-24 |
| JP2025513502A5 JP2025513502A5 (cg-RX-API-DMAC7.html) | 2026-05-08 |
Family
ID=86316741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024562212A Pending JP2025513502A (ja) | 2022-04-22 | 2023-04-24 | 液体組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250268896A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4511003A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513502A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403543A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249515A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202408516A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023203258A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| PT3366278T (pt) | 2006-06-23 | 2024-10-21 | Janssen Sciences Ireland Unlimited Co | Suspensões aquosas de tmc278 |
| WO2009128917A2 (en) * | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| AU2020344675B2 (en) * | 2019-09-13 | 2026-06-25 | Halozyme Hypercon, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| WO2022109555A1 (en) | 2020-11-17 | 2022-05-27 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
-
2023
- 2023-04-24 CN CN202380048796.5A patent/CN119403543A/zh active Pending
- 2023-04-24 TW TW112115225A patent/TW202408516A/zh unknown
- 2023-04-24 US US18/858,242 patent/US20250268896A1/en active Pending
- 2023-04-24 CA CA3249515A patent/CA3249515A1/en active Pending
- 2023-04-24 WO PCT/EP2023/060689 patent/WO2023203258A1/en not_active Ceased
- 2023-04-24 EP EP23722289.8A patent/EP4511003A1/en active Pending
- 2023-04-24 JP JP2024562212A patent/JP2025513502A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4511003A1 (en) | 2025-02-26 |
| CN119403543A (zh) | 2025-02-07 |
| WO2023203258A1 (en) | 2023-10-26 |
| CA3249515A1 (en) | 2023-10-26 |
| US20250268896A1 (en) | 2025-08-28 |
| TW202408516A (zh) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2317319T3 (es) | Emulsiones oftalmicas que contienen un agente inmunosupresor. | |
| DK2040671T3 (en) | AURAL SUSPENSIONS OF TMC278 | |
| JP2009507925A (ja) | ナノ粒子タダラフィル製剤 | |
| JP2006508105A (ja) | ナノ粒子状フィブラート製剤 | |
| KR20090015994A (ko) | 나노입자형 포사코나졸 제제 | |
| EP4178540A1 (en) | Long-acting formulations | |
| US20250268896A1 (en) | Liquid compositions | |
| US20250275967A1 (en) | Freeze dried compositions | |
| Sigfridsson et al. | A Practical Guide for the Preparation of Drug Nanosuspensions for Preclinical Studies: Including In Vivo Case Studies | |
| JP2023549837A (ja) | 疾患又は障害の治療又は予防 | |
| TW202333725A (zh) | 溶出測試 | |
| CN118251210A (zh) | 溶出测试 | |
| HK40113410A (en) | Dissolution test | |
| KR101811314B1 (ko) | Hiv 감염의 치료 및 예방 | |
| WO2023222754A1 (en) | Rilpivirine for use in the treatment or prevention of hiv infection | |
| WO2024068693A1 (en) | Long-acting formulations | |
| AU2016219555B2 (en) | Aqueous suspensions of TMC278 | |
| CN116437923A (zh) | Hiv感染的治疗或预防 | |
| EP4593834A1 (en) | Long-acting formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250319 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260424 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260424 |